Silence Therapeutics PLC Silence to present SL124 data at EHA (9477A)
June 07 2021 - 1:00AM
UK Regulatory
TIDMSLN
RNS Number : 9477A
Silence Therapeutics PLC
07 June 2021
Silence Therapeutics to Present Data Highlighting Broad
Therapeutic Potential for SLN124 at the European Hematology
Association (EHA) 2021 Virtual Congress
- Preclinical data at EHA support recently reported positive
topline clinical data for SLN124 in healthy volunteers
- SLN124 is being evaluated in the ongoing GEMINI II phase 1
study in patients with thalassemia and myelodysplastic syndrome
7 June 2021
LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN ("
Silence " or " the Company "), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announced that it will
present data showing the potential for SLN124 to address a range of
hematological diseases by targeting the liver-expressed gene
TMPRSS6 during two poster sessions at the European Hematology
Association (EHA) Virtual Congress to be held on June 9-17,
2021.
The presentations include a preclinical safety assessment of
SLN124 which will show data that are consistent with recent
positive topline clinical data from the GEMINI phase 1 study of
SLN124 in healthy volunteers announced last month (press release
linked here ). SLN124 is being evaluated in the ongoing GEMINI II
phase 1 study in patients with thalassemia and myelodysplastic
syndrome. A second poster will present encouraging preclinical
evidence that using siRNA to target TMPRSS6 could be a viable
therapeutic avenue for treatment of the rare blood disorder,
polycythaemia vera (PV).
E-posters will be available for registered attendees through the
EHA Virtual Congress platform starting Friday, June 11, 09:00
CEST.
Details on the presentations are as follows:
Title: Non-clinical safety of SLN124, a GalNAc conjugated 19-mer
double stranded siRNA targeting TMPRSS6 facilitating evaluation in
clinical studies
Abstract #: EP846 ( link here )
Session Topic: Iron metabolism, deficiency and overload
Title: Anti-TMPRSS6 RNAi Therapy as a Novel Treatment Option for
Polycythaemia Vera
Abstract #: EP1057 ( link here )
Session Topic: Myeloproliferative neoplasms - Biology &
Translational Research
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20 7597
Broker) 5970
Daniel Adams/Gary Clarence
European IR Tel: +44 (0) 20 3709
Consilium Strategic Communications 5700
Mary-Jane Elliott/ Angela Gray / Chris
Welsh
silencetherapeutics@consilium-comms.com
About SLN124
SLN124 is a gene 'silencing' therapy - one that is designed to
temporarily block a specific gene's message that would otherwise
trigger an unwanted effect. In this case, SLN124 aims to
temporarily 'silence' TMPRSS6, a gene that prevents the liver from
producing a particular hormone that controls iron levels in the
body - hepcidin. As hepcidin increases, it is hoped that iron
levels in the blood will decrease, which could in turn allow more
healthy red blood cells to be produced, thereby improving
anemia.
In preclinical studies, SLN124 showed a strong safety profile
and positive effects on improving levels of red blood cells and
reducing harmful iron levels. Data from the recently completed
GEMINI phase 1 study of SLN124 in healthy volunteers demonstrated
SLN124 was safe and effective in reducing plasma iron levels and
had a long duration of action. These data support the ongoing
GEMINI II phase 1 study of SLN124 in people with thalassemia or
myelodysplastic syndrome (MDS), whose bodies produce fewer healthy
red blood cells than normal and who can store too much iron in
their bodies. For more information on the GEMINI II study, please
click here .
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
need. Silence's proprietary mRNAi GOLD(TM) platform can be used to
create siRNAs (short interfering RNAs) that precisely target and
silence disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address
iron-loading anemia conditions. Silence also maintains ongoing
research and development collaborations with AstraZeneca,
Mallinckrodt Pharmaceuticals, and Takeda, among others. For more
information, please visit https://www.silence-therapeutics.com/
.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and other securities laws, including
with respect to the Company's clinical and commercial prospects and
the anticipated timing of data reports from the Company's clinical
trials. These forward-looking statements are not historical facts
but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements,
including those risks identified in the Company's most recent
Admission Document and its amended Annual Report on Form 20-F filed
with the U.S. Securities and Exchange Commission on April 29, 2021.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBRGDLCSGDGBS
(END) Dow Jones Newswires
June 07, 2021 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024